Center for Experimental Drugs & Diagnostics

Therapeutic Approaches: Small Molecules, Biomarkers, Stem Cells

Therapeutic Areas of Expertise: Neurological Disorders, Psychiatric Disorders, Regenerative Medicine

Center/Program Highlights: The MGH Psychiatry Center for Experimental Drugs and Diagnostics (CEDD) focuses on bringing new discoveries in neuroscience and genetics to the clinic. Our mission includes developing and beginning clinical investigation of novel therapeutics as well as diagnostic tests and other tools to improve patient outcomes. A particular focus of our drug discovery strategies is on the creation and use of patient-specific, induced pluripotent stem cells (iPSCs) and induced neurons (iNs) models for identifying and validating novel treatment targets through high-throughput, phenotype-based drug and functional genomic screens. These same cellular models are being used for phenotyping to understand treatment response and to aid in patient stratification in conjunction with genomic analysis.

Sources of Funding: Federal/State, Philanthropy, Industry Partnerships, Disease Foundations, University


Institutional Affiliation(s): Massachusetts General Hospital Harvard Medical School

Massachusetts General Hospital
185 Cambridge Street
Massachusetts, 02114
United States

Center/Program Start Date: 2007

Number of Employees: 15